肝动脉灌注栓塞—肿瘤树突状细胞免疫介入治疗肝癌45例

Immune intervention with transcatheter hepatic arterial chemoembolization combined dendritic cells for 45 hepatic carcinoma cases

目的探讨经肝动脉灌注栓塞—肿瘤树突状细胞免疫（TACE-DCs）介入治疗肝癌的临床疗效。方法2009年2月~2012年8月,我院对45例肝癌患者行肝动脉灌注栓塞—肿瘤树突状细胞免疫治疗,灌注抗癌药物为5-Fu 500 mg,羟喜树碱20 mg,表阿霉素30~40 mg;40%碘化油5~10 mL进行肝动脉栓塞;树突状细胞辅助治疗。结果 45例均成功施行肝动脉灌注栓塞术并应用树突状细胞治疗。手术成功率100%,总有效率91.1%（41/45）。患者肝癌均有不同程度缩小,AFP也不同程度的下降。1、2和3年生存率分别为88.8%（40/45）、71.1%（32/45）和51.1%（23/45）。结论 TACE-DCs治疗肝癌临床疗效好,创伤小、并发症少、安全。

[Objective ] To observe the clinical effectiveness of forty-five patients who were treated by the tran- scatbeter arterial chemoembolization（TACE） and dendritic cells （DCs）. [ Methods ] The forty-five patients were treat- ed by the TACE combined DCs from February 2009 to August 2012. The chemotherapeutic agents were 5-Fu （500 mg）, hydroxycamptothecin （20 rag）, epirubicin （30-40 mg） and lipiodol （5-10 mL）. [Results] The arterial infusion and embolization were successfully administered in all forty-five cases. The total response rate （CR＋PR） was 91.1% （41/45）. The survival rate at 1-, 2-, 3-year was 88.8% （40/45）, 71.1% （32/45）, 51.1% （23/45）, respectively. [Con- clusion ] The treatment of hepatic cancer by the TACE combined DCs offers good clinical effects, small wound, few complications and safe.